Geographic differences in the distribution of molecular subtypes of breast cancer in Brazil

BMC Women's Health

Volumn 14, Issue 1, 2014, Pages

  Carvalho, Filomena M ^a   Bacchi, Lívia M ^a   Pincerato, Kátia M ^a   Van de Rijn, Matt ^b   Bacchi, Carlos E ^c  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b STANFORD UNIVERSITY MEDICAL CENTER   (United States)

^c Stanford University Medical Center ^*  (Brazil)

Author keywords

Brazilian races; Breast cancer; Epidemiology; Intrinsic molecular subtypes

Indexed keywords

CYTOKERATIN 5; CYTOKERATIN 6; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; VASCULOTROPIN RECEPTOR; TUMOR MARKER;

ADOLESCENT; ADULT; AFRICAN; AGED; ARTICLE; BRAZIL; BREAST CANCER; CANCER CLASSIFICATION; COMPARATIVE STUDY; CONTROLLED STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 NEGATIVE BREAST CANCER; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; ESTROGEN RECEPTOR NEGATIVE BREAST CANCER; EUROPEAN; FEMALE; GEOGRAPHIC DISTRIBUTION; GEOGRAPHY; HUMAN; IMMUNOHISTOCHEMISTRY; INCIDENCE; LUMINAL A BREAST CANCER; LUMINAL B BREAST CANCER; MAJOR CLINICAL STUDY; MIDDLE AGED; OBSERVATIONAL STUDY; ONSET AGE; PROGESTERONE RECEPTOR NEGATIVE BREAST CANCER; PROGESTERONE RECEPTOR POSITIVE BREAST CANCER; RETROSPECTIVE STUDY; SOCIAL STATUS; TRIPLE NEGATIVE BREAST CANCER; TRIPLE POSITIVE BREAST CANCER; AGE; BLACK PERSON; BREAST NEOPLASMS; CARCINOMA; CAUCASIAN; METABOLISM; MOLECULAR EPIDEMIOLOGY; STATISTICS AND NUMERICAL DATA; TRIPLE NEGATIVE BREAST NEOPLASMS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AFRICAN CONTINENTAL ANCESTRY GROUP; AGE FACTORS; AGED; AGED, 80 AND OVER; BRAZIL; BREAST NEOPLASMS; CARCINOMA; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MIDDLE AGED; MOLECULAR EPIDEMIOLOGY; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TRIPLE NEGATIVE BREAST NEOPLASMS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84929130747     PISSN: None     EISSN: 14726874     Source Type: Journal    
DOI: 10.1186/1472-6874-14-102     Document Type: Article

References (35)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin 2011, 61(2):69-90.
2. Perou CM, Sorlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, Pollack JR, Ross DT, Johnsen H, Akslen LA, Fluge O, Pergamenschikov A, Williams C, Zhu SX, Lønning PE, Børresen-Dale AL, Brown PO, Botstein D: Molecular portraits of human breast tumours. Nature 2000, 406(6797):747-752.
3. Caudle AS, Yu TK, Tucker SL, Bedrosian I, Litton JK, Gonzalez-Angulo AM, Hoffman K, Meric-Bernstam F, Hunt KK, Buchholz TA, Mittendorf EA: Localregional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving therapy. Breast Cancer Res 2012, 14(3):R83.
4. Esserman LJ, Berry DA, Cheang MC, Yau C, Perou CM, Carey L, DeMichele A, Gray JW, Conway-Dorsey K, Lenburg ME, Buxton MB, Davis SE, van't Veer LJ, Hudis C, Chin K, Wolf D, Krontiras H, Montgomery L, Tripathy D, Lehman C, Liu MC, Olopade OI, Rugo HS, Carpenter JT, Livasy C, Dressler L, Chhieng D, Singh B, Mies C, Rabban J, et al: Chemotherapy response and recurrence-free survival in neoadjuvant breast cancer depends on biomarker profiles: results from the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657). Breast Cancer Res Treat 2012, 132(3):1049-1062.
5. Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K, Yoshida T, Fujiwara Y, Tamura K: Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells. Cancer Sci 2012, 103(9):1665-1671.
6. Martín M, Rodríguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz-Borrego M, Santaballa A, Rodríguez CA, Crespo C, Abad M, Domínguez S, Florián J, Llorca C, Méndez M, Godes M, Cubedo R, Murias A, Batista N, García MJ, Caballero R, de Alava E: Molecular predictors of efficacy of adjuvant weekly paclitaxel in early breast cancer. Breast Cancer Res Treat 2010, 123(1):149-157.
7. Carey LA, Perou CM, Livasy CA, Dressler LG, Cowan D, Conway K, Karaca G, Troester MA, Tse CK, Edmiston S, Deming SL, Geradts J, Cheang MC, Nielsen TO, Moorman PG, Earp HS, Millikan RC: Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006, 295(21):2492-2502.
8. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V: Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 2007, 109(9):1721-1728.
9. Yang XR, Sherman ME, Rimm DL, Lissowska J, Brinton LA, Peplonska B, Hewitt SM, Anderson WF, Szeszenia-Dabrowska N, Bardin-Mikolajczak A, Zatonski W, Cartun R, Mandich D, Rymkiewicz G, Ligaj M, Lukaszek S, Kordek R, García-Closas M: Differences in risk factors for breast cancer molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev 2007, 16(3):439-443.
10. Kwan ML, Kushi LH, Weltzien E, Maring B, Kutner SE, Fulton RS, Lee MM, Ambrosone CB, Caan BJ: Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009, 11(3):R31.
11. Chuang E, Paul C, Flam A, McCarville K, Forst M, Shin S, Vahdat L, Swistel A, Simmons R, Osborne M: Breast cancer subtypes in Asian-Americans differ according to Asian ethnic group. J Immigr Minor Health 2012, 14(5):754-758.
12. Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA: Molecular breast cancer subtypes in premenopausal African-American women, tumor biologic factors and clinical outcome. Ann Surg Oncol 2007, 14(10):2994-3003.
13. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD, DeWitty RL, Frederick WA: Treatment and survival outcome for molecular breast cancer subtypes in black women. Ann Surg 2008, 247(3):463-469.
14. Chlebowski RT, Chen Z, Anderson GL, Rohan T, Aragaki A, Lane D, Dolan NC, Paskett ED, McTiernan A, Hubbell FA, Adams-Campbell LL, Prentice R: Ethnicity and breast cancer: factors influencing differences in incidence and outcome. J Natl Cancer Inst 2005, 97(6):439-448.
15. 2010 Population Census. http://www.ibge.gov.br/english/estatistica/populacao/censo2010/default.shtm.
16. Telles E: Racial ambiguity among the Brazilian population. Ethnic Racial Stud 2002, 25(3):415-441.
17. Parra FC, Amado RC, Laübertucci JR, Rocha J, Antunes CM, Pena SD: Color and genomic ancestry in Brazilians. Proc Natl Acad Sci U S A 2003, 100(1):177-182.
18. Pena SD, Di Pietro G, Fuchshüber-Moraes M, Genro JP, Hutz MH, Kehdy FS, Kohlrausch F, Magno LA, Montenegro RC, Moraes MO, de Moraes ME, de Moraes MR, Ojopi EB, Perini JA, Racciopi C, Ribeiro-Dos-Santos AK, Rios-Santos F, Romano-Silva MA, Sortica VA, Suarez-Kurtz G: The genomic ancestry of individuals from different geographical regions of Brazil is more uniform than expected. PLoS One 2011, 6(2):e17063.
19. Estimativa 2014. Incidência de Câncer no Brasil. http://www.inca.gov.br/estimativa/2014/estimativa-24042014.pdf.
20. Wolff AC, Hammond ME, Schwartz JN, Hagerty KL, Allred DC, Cote RJ, Dowsett M, Fitzgibbons PL, Hanna WM, Langer A, McShane LM, Paik S, Pegram MD, Perez EA, Press MF, Rhodes A, Sturgeon C, Taube SE, Tubbs R, Vance GH, van de Vijver M, Wheeler TM, Hayes DF, American Society of Clinical Oncology; College of American Pathologists: American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007, 25(1):118-145.
21. Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, Watson M, Davies S, Bernard PS, Parker JS, Perou CM, Ellis MJ, Nielsen TO: Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009, 101(10):736-750.
22. Nielsen TO, Hsu FD, Jensen K, Cheang M, Karaca G, Hu Z, Hernandez-Boussard T, Livasy C, Cowan D, Dressler L, Akslen LA, Ragaz J, Gown AM, Gilks CB, van de Rijn M, Perou CM: Immunohistochemical and clinical characterization of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res 2004, 10(16):5367-5374.
23. Ihemelandu CU, Naab TJ, Mezghebe HM, Makambi KH, Siram SM, Leffall LD, Dewitty RL, Frederick WA: Basal cell-like (triple-negative) breast cancer, a predictor of distant metastasis in African American women. Am J Surg 2008, 195(2):153-158.
24. Lantz PM, Mujahid M, Schwartz K, Janz NK, Fagerlin A, Salem B, Liu L, Deapen D, Katz SJ: The influence of race, ethnicity, and individual socioeconomic factors on breast cancer stage at diagnosis. Am J Public Health 2006, 96(12):2173-2178.
25. Smigal C, Jemal A, Ward E, Cokkinides V, Smith R, Howe HL, Thun M: Trends in breast cancer by race and ethnicity: update 2006. CA Cancer J Clin 2006, 56(3):168-183.
26. Kurian AW, Fish K, Shema SJ, Clarke CA: Lifetime risks of specific breast cancer subtypes among women in four racial/ethnic groups. Breast Cancer Res 2010, 12(6):R99.
27. Ihemelandu CU, Leffall LD, Dewitty RL, Naab TJ, Mezghebe HM, Makambi KH, Adams-Campbell L, Frederick WA: Molecular breast cancer subtypes in premenopausal and postmenopausal African-American women: agespecific prevalence and survival. J Surg Res 2007, 143(1):109-118.
28. Dunn BK, Agurs-Collins T, Browne D, Lubet R, Johnson KA: Health disparities in breast cancer: biology meets socioeconomic status. Breast Cancer Res Treat 2010, 121(2):281-292.
29. Harper S, Lynch J, Meersman SC, Breen N, Davis WW, Reichman MC: Trends in area-socioeconomic and race-ethnic disparities in breast cancer incidence, stage at diagnosis, screening, mortality, and survival among women ages 50 years and over (1987-2005). Cancer Epidemiol Biomarkers Prev 2009, 18(1):121-131.
30. Clarke CA, Keegan TH, Yang J, Press DJ, Kurian AW, Patel AH, Lacey JV: Age-specific incidence of breast cancer subtypes: understanding the black-white crossover. J Natl Cancer Inst 2012, 104(14):1094-1101.
31. Cunningham JE, Montero AJ, Garrett-Mayer E, Berkel HJ, Ely B: Racial differences in the incidence of breast cancer subtypes defined by combined histologic grade and hormone receptor status. Cancer Causes Control 2010, 21(3):399-409.
32. Goldhirsch A, Wood WC, Coates AS, Geüber RD, Thürlimann B, Senn HJ, Meübers P: Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 2011, 22(8):1736-1747.
33. Wang S, Dorsey TH, Terunuma A, Kittles RA, Ambs S, Kwabi-Addo B: Relationship between tumor DNA methylation status and patient characteristics in African-American and European-American women with breast cancer. PLoS One 2012, 7(5):e37928.
34. Barnholtz-Sloan JS, Shetty PB, Guan X, Nyante SJ, Luo J, Brennan DJ, Millikan RC: FGFR2 and other loci identified in genome-wide association studies are associated with breast cancer in African-American and younger women. Carcinogenesis 2010, 31(8):1417-1423.
35. Januszewski A, Tanna N, Stebbing J: Ethnic variation in breast cancer incidence and outcomes-the debate continues. Br J Cancer 2014, 110(1):4-6.